MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Cardiovascular / Structural Heart / Cardiac Implants / FDA: Abiomed Impella RP survival rate steady when appropriate patients are implanted

FDA: Abiomed Impella RP survival rate steady when appropriate patients are implanted

December 3, 2019 By Nancy Crotti Leave a Comment

Abiomed's Impella RPThe survival rate of right-heart failure patients treated with the Abiomed (NSDQ:ABMD) Impella RP heart pump remained about the same during the latest round of post-approval studies, according to the FDA.

That latest rate of survival 30 days post-explant, post-discharge survival or switch to another therapy rate was 72.7%, or 16 out of 22 patients among those who would have met the enrollment criteria for the premarket clinical studies. This compares with the 73.3% rate among those who met the same criteria and participated in those premarket studies, the agency noted.

Among patients who would not have qualified for Impella RP using the preclinical trial criteria, the most current survival rate was 13.6%, or six out of 44 patients. This latter group includes patients who were more likely to have been in cardiogenic shock for longer than 48 hours, experienced a cardiac arrest, or suffered a pre-implant hypoxic or ischemic neurologic event before having Impella implanted, the FDA said. A total of 60 patients are enrolled in the study.

The agency said in February that it was concerned with the  17% overall survival rate of Impella RP post-approval study patients, of whom four out of 23 had met the primary survival endpoint. In April, the FDA approved revised labeling for Impella RP to include more information about patient selection and which patients may benefit the most from treatment with the device. The agency also required Abiomed to make changes to the design of the post-approval study to include subgroup analyses, and to establish a minimum number of patients in each subgroup. Details of the study protocol are posted on the FDA’s post-approval studies webpage.

Abiomed said that nearly two years of real-world outcomes on its Impella RP heart pump show that when physicians followed the FDA’s approved protocol for Impella RP use, which includes early identification of right heart failure and early implantation of Impella RP, they achieved 72% patient survival and 88% native heart recovery. Investigators and thought leaders in the field of cardiogenic shock have made multiple recommendations based on data sets which demonstrate late identification of right heart failure is associated with increased mortality, the company added.

“We are pleased to see the numerical increase in survival for both the Recover Right and salvage populations in the Impella RP post approval study,” added Dr. Seth Bilazarian, an interventional cardiologist and Abiomed’s chief medical officer, in an email to MassDevice. “The FDA’s letters to health care providers earlier this year have helped Abiomed and the post-approval study principal investigators educate other medical providers on the importance of using simple identifiers to achieve timely identification of right side heart failure in the catheterization lab and ICU.”

In a May 21 letter to cardiologists, cardiothoracic surgeons and and transplant surgeons, the agency said it believed that when the device is used for the currently approved indication in appropriately selected patients, the benefits of the Impella RP system continue to outweigh the risks.

Abiomed won clearance for the Impella RP in September of 2017,  and it remains the only device with FDA premarket approval for right-side heart support. Much like the company’s flagship Impella heart pump, the Impella RP is threaded into the heart via the femoral artery in the thigh. But unlike previous Impella models, all designed for the heart’s left ventricle, the Impella RP is designed to access the heart’s right ventricle via the vena cava.

The next post-approval study report on Impella RP is due March 20, 2020. The FDA said it will continue to post interim results from the ongoing study on the post-approval studies webpage.

Shares of ABMD took a 20% hit Nov. 18 after new research suggested potentially serious complications involving the company’s Impella heart pumps. Abiomed said at the time that the research was flawed.

Shares of ABMD were trading down 0.68% at $190.92 at noon today.

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Food & Drug Administration (FDA), Regulatory/Compliance, Wall Street Beat Tagged With: Abiomed, FDA

In case you missed it

  • Bio-Rad recovering from ransomware attack
  • FDA clears first single-use duodenoscope from Boston Sci
  • FDA approves Tandem Diabetes’ advanced hybrid closed-loop controller
  • Awak Technologies raises $40m
  • Axonics raises additional $17m in public offering
  • Siemens Healthineers lands FDA clearance for two CT systems
  • Aethlon prices $5m offering
  • Sterigenics’ legal troubles mount in Illinois
  • In2Bones launches AlloAid BioNail
  • Caresyntax to acquire Syus; raises $45.6m
  • Nihon Kohden launches new patient monitor
  • Senate confirms Dr. Stephen Hahn to lead FDA
  • Iradimed renews CE mark for MRI-safe patient monitor
  • Flexicare recalls fiber optic laryngoscope blades and handles
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
  • TransEnterix announces reverse split of common stock
  • GI Windows raises $15m Series A

RSS From Medical Design & Outsourcing

  • Sterigenics’ legal troubles mount in Illinois
    Nearly two dozen new lawsuits were filed against Sterigenics this week over its now-shuttered ethylene oxide (EtO) sterilization plant in Willowbrook, Ill., according to a law firm representing some of the plaintiffs. That brings the total of such lawsuits to nearly 75, noted Chicago personal injury lawyer Antonio Romanucci, court-appointed lead counsel from among five… […]
  • In2Bones launches AlloAid BioNail
    In2Bones this week launched its AlloAid BioNail sterile allograft implant. The implant is designed to give rigid, stable fixation during hand and foot reconstruction. AlloAid BioNail is made from strong cortical allografts to provide osteoconductive properties for bone remodeling and healing. It features a tapered point and multiple, contoured wedge facets to ease insertion, anchor… […]
  • Protolabs’ healthcare grant spurs 2 feeding tube inventions
    Digital manufacturer Protolabs (NYSE:PRLB) announced today that MedStar Health (Columbia, Md.) and Cleveland Clinic Innovations are joint winners of the company’s Cool Idea Award: Healthcare Grant. These grants provide in-kind manufacturing services to the support development of medical products to spur innovation in the field. MedStar Health’s gravity-feed syringe holder simplifies the feeding of newborns… […]
  • Nihon Kohden launches new patient monitor
    Nihon Kohden (TYO:6849) announced the U.S. launch of its Life Scope SVM-7200 series vital signs monitor for outpatient facilities and beds that aren’t continuously monitored. The Life Scope SVM-7200 is designed to provide customizable early warning scoring to help clinicians identify patients who are deteriorating or at risk of deterioration. It combines vital signs data with… […]
  • Senate confirms Dr. Stephen Hahn to lead FDA
    The U.S. Senate has confirmed Dr. Stephen Hahn as the next commissioner of the FDA. The vote was 72 to 18, according to a report in the New York Times. Hahn will be the first permanent commissioner of the agency since Dr. Scott Gottlieb resigned in April. President Trump nominated Hahn, the chief medical officer at Houston’s… […]
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
    3M (NYSE:MMM) announced today that it entered into an agreement to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for approximately $650 million. St. Paul, Minn.-based 3M will retain its transdermal drug delivery components business, according to a news release. The business being divested has annual global sales reaching approximately… […]
  • Lawsuit endangers Sterigenics consent order in Georgia
    A consent order that Sterigenics entered into with the state of Georgia to reduce ethylene oxide (EtO) emissions at its Atlanta medtech sterilization plant may be in jeopardy. A hearing is scheduled today on a lawsuit that accuses the Georgia Environmental Protection Division (EPD) of failing to take public comment before entering the Aug. 7… […]
  • Trelleborg acquires Tritec Seal
    Trelleborg Sealing Solutions said today it has closed on its acquisition of rotary seal manufacturer Tritec Seal, which produces engineered polytetrafluoroethylene (PTFE) sealing solutions. Trelleborg said the acquisition strengthens its product portfolio while giving the business area access to increased manufacturing capacity. Headquartered in Fenton, Mich., with additional manufacturing in Giddings, Texas, Tritec Seal generated… […]
  • RSNA 2019: 7 radiology innovations you need to know
    Nearly 53,000 people attended the 2019 Radiological Society of North America annual meeting in Chicago last week. And they heard the same acronym over and over again: AI. Exhibitors at the conference touted their artificial-intelligence-enhanced technology at every turn, claiming to make images clearer, sharper, easier to use and powerful enough to help clinicians make… […]
  • Employees say Intuitive Surgical, J&J, Stryker best places to work in 2020
    Intuitive Surgical (NSDQ:ISRG), Johnson & Johnson (NYSE:JNJ) and Stryker (NYSE:SYK) were recently named as Glassdoor’s employees’s choice of Best Places to Work in 2020. Each year, Glassdoor uses feedback that employees have shared on the website over the past year to compile a list of the best places to work in 2020. Employee reviews provide Glassdoor with insights into job and… […]
  • Biolase lands 510(k) for dental hygiene laser
    Biolase (NSDQ:BIOL) this week announced it has received FDA 510(k) clearance for its Epic Hygiene dental laser. The laser system allows dental hygienists to manage non-surgical periodontitis and increase clinical production. It offers a step-by-step clinical protocol with pocket therapy and perio debridement for easy implementation. Get the full story on our sister site, MassDevice. The […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS